Century Therapeutics (IPSC) vs X4 Pharmaceuticals (XFOR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Century Therapeutics (IPSC) has outperformed X4 Pharmaceuticals (XFOR) over the past year, gaining 150.0% versus a loss of 16.0%. Over five years, IPSC leads with a -92.4% price change compared with -98.2% for XFOR. X4 Pharmaceuticals is the larger company by market cap ($276.6 million vs $264.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IPSC | XFOR |
|---|---|---|
| Share price | $1.46 | $2.79 |
| Market cap | $264.37M | $276.62M |
| 1-day change | +14.06% | -0.71% |
| YTD return | +46.73% | -30.25% |
| 1-year return | +150.00% | -15.96% |
| 5-year return | -92.44% | -98.22% |
| P/E ratio (TTM) | — | 139.50 |
| EPS (TTM) | $-0.93 | $0.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.04 | $4.83 |
| 52-week low | $0.435 | $2.70 |
| Distance from 52-week high | -51.97% | -42.24% |
| Analyst consensus | buy | none |
| Avg. price target upside | +225.34% | +315.77% |
| Average volume | 649.61K | 849.58K |
| Shares outstanding | 181.08M | 99.15M |
| Employees | 78 | 45 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IPSC has outperformed XFOR by 166.0 percentage points over the past year.
About Century Therapeutics
IPSC stock →Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 78 employees
About X4 Pharmaceuticals
XFOR stock →X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 45 employees
IPSC vs XFOR FAQ
Which is bigger, Century Therapeutics or X4 Pharmaceuticals?
X4 Pharmaceuticals (XFOR) is larger, with a market capitalization of $276.62M compared with $264.37M for Century Therapeutics (IPSC).
Which stock has performed better over the past year, IPSC or XFOR?
IPSC returned +150.00% over the past 12 months, compared with -15.96% for XFOR (price return, excluding dividends). Past performance does not predict future results.
Are Century Therapeutics and X4 Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.